

Study to explore whether Andrographis (a herbal medicine) can help to treat sore throats, coughs and colds (acute respiratory tract infections (ARTIs))

Submission date 06/12/2018	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/01/2019	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 04/07/2019	Condition category Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Acute respiratory infections (ARTIs) such as cough, sore throat and sinusitis are common, distressing and costly both for individuals and the NHS. Antibiotics have limited benefits in most ARTIs and commonly have side effects. A herbal medicine called Andrographis (*Andrographis paniculata*) is a promising candidate to treat ARTIs. Andrographis extract is derived from the leaf of the plant *Andrographis paniculata*. Andrographis is currently used in Western, Ayurvedic and Chinese herbal traditional medicines for respiratory and digestive illnesses. Results from multiple trials suggests that Andrographis performed better than placebo after 5-7 days. This study aims to investigate the feasibility of carrying out a trial of providing Andrographis capsules to adults who visit their GP with ARTI symptoms, where the GP thinks the symptoms are caused by an infection (bacterial or viral) but NOT pneumonia. It aims to find out whether patients find it acceptable to take the Andrographis capsules, whether enough patients can be recruited into the study, whether the people involved complete the study documents, and how many of the patients complete the study diary after the treatments have been given. The investigators have previously completed interviews with health professionals treating patients in order to understand the issues around herbal medicines for ARTIs, and this has helped us design this feasibility study.

Who can participate?

Patients aged 18 or over who have visited their GP surgery with a sore throat, acute cough (less than 7 days' duration) or cold where pneumonia is not suspected.

What does the study involve?

Participants will be randomly allocated to receive capsules containing 250 mg Andrographis *paniculata* or placebo (dummy) capsules (capsules that look, taste and smell the same but have no active ingredients) for a week. They will be asked to take 3 capsules 4 times a day with water before food. Treatments will be randomly allocated and double-blinded (meaning that no one, including the doctor and the participant, will know which participant is getting which treatment).

Both groups will continue to receive standard care and GPs can prescribe antibiotics if needed to participants in either group, either taken immediately, or issued as a delayed prescription. The GP will decide which antibiotic is prescribed. Participants will be asked to wait 7-10 days before collecting the delayed prescription unless their symptoms show substantial worsening.

What are the possible benefits and risks of participating?

It is not known whether participants will have any additional benefit from taking part in this trial. However their participation will help to give important information about how best to treat people with ARTIs in the future. It is unlikely but participants may experience mild side effects from taking the trial medication.

Where is the study run from?

University of Southampton (UK)

When is the study starting and how long is it expected to run for?

June 2017 to August 2019

Who is funding the study?

Pukka Herbs (UK)

Who is the main contact?

1. Mrs Jackie Seeley, GRAPHALO@soton.ac.uk

2. Mr Martin Logue, GRAPHALO@soton.ac.uk

Contact information

Type(s)

Scientific

Contact name

Mrs Jackie Seely

Contact details

University of Southampton
Primary Care & Population Sciences
Aldermoor Health Centre
Aldermoor Close
Southampton
United Kingdom
SO16 6YD
+44 (0)23 8052 2289
GRAPHALO@soton.ac.uk

Type(s)

Scientific

Contact name

Mr Martin Logue

ORCID ID

<http://orcid.org/0000-0002-7393-0618>

Contact details

University of Southampton
Primary Care & Population Sciences
Aldermoor Health Centre
Aldermoor Close
Southampton
United Kingdom
SO16 5ST
+44 (0)23 8052 2289
GRAPHALO@soton.ac.uk

Additional identifiers**EudraCT/CTIS number****IRAS number**

208314

ClinicalTrials.gov number**Secondary identifying numbers**

IRAS 208314

Study information**Scientific Title**

GRAPHALO: A double blind randomised placebo controlled feasibility study evaluating the effect of Andrographis paniculata (Immunographis) in the treatment of adults with acute respiratory tract infections (ARTIs)

Acronym

GRAPHALO

Study objectives

Acute respiratory infections (ARTIs) (such as cough, sore throat and sinusitis) are common, distressing, and costly both for individuals and the NHS. Antibiotics have limited benefits in most ARTIs and commonly have side effects. A herbal medicine called Andrographis (Andrographis paniculata) is a promising candidate to treat acute respiratory tract infections. In a recent systematic review of randomised controlled trials, Andrographis performed better than placebo after 5-7 days. The main objective of this trial is to determine the feasibility of running a full-scale trial of Andrographis paniculata leaf extract in a UK primary care setting.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Hampshire B Research Ethics Committee and the Health Research Authority, 22/11/2018, ref: 208314, University of Southampton Ethics and Research Governance Online (ERGO) number: 27851

Study design

Double-blind placebo-controlled randomised feasibility study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Acute respiratory tract infections with symptoms such as cough, sore throat, fever and muscle ache where pneumonia is not suspected

Interventions

This is a multicentre, double-blind placebo-controlled feasibility study of *Andrographis paniculata* leaf extract. The study aims to recruit 60 participants.

Patients will be eligible for the trial if they are over 18 years of age and present to their GP with a potential ARTI. Adults 18 years and over presenting with an acute cough (≤ 7 days' duration) or sore throat as their main symptom and, with symptoms localising to the upper respiratory tract (e.g. runny nose, sneezing, fever, muscle ache), for which non-infective diagnoses are judged very unlikely.

Participants will be randomised to 1 week of active treatment using *Andrographis* capsules or placebo. The capsules contain 250 mg of dried *Andrographis paniculata*. Participants will take 3 capsules 4 times a day with water before food. Treatments will be randomly allocated and double-blinded so that no one, including the doctor and the participant, will know which participant is getting which treatment. Both groups will continue to receive standard care and GPs can prescribe antibiotics if needed to participants in either group, either taken immediately, or issued as a delayed prescription.

Intervention Type

Supplement

Primary outcome measure

All of the feasibility timepoints will be evaluated after the study finishes (16 weeks):

1. Feasibility of eligibility criteria, assessed using number of patients included and number excluded (and reasons for exclusion) from the trial recorded in on-site screening logs
2. Feasibility of recruitment (ability to recruit patients into the intervention from those attending primary care) assessed using on-site enrolment record, with monthly rate/site adjusted for site list size.

3. Feasibility of randomisation (willingness to be randomised) assessed using the proportion of eligible patients recruited
4. Retention rate calculated from records of enrolment, withdrawal and completed diaries returned after 2 weeks
5. Intervention compliance assessed using patient-record diary data and returned intervention capsules
6. Suitability of the patient diaries and patients' willingness to complete them and the importance of telephone/text contact from quantitative data collection - percentage of patients returning completed diaries

Secondary outcome measures

Rates of antibiotic prescription assessed using the participant's record in the diary of the day they started taking antibiotics, evaluated after the study finishes (16 weeks)

Overall study start date

14/06/2017

Completion date

31/08/2019

Eligibility

Key inclusion criteria

1. Aged over 18 years
2. Present to GP with a potential ARTI
3. Acute cough (≤ 7 days' duration) or sore throat as main symptom
4. Symptoms localising to the upper respiratory tract (e.g. runny nose, sneezing, fever, muscle ache), for which non-infective diagnoses are judged very unlikely
5. Willing and able to give written informed consent.

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned sample size: 60

Total final enrolment

38

Key exclusion criteria

1. Pregnant (or suspected to be pregnant) or breast feeding; patients who become pregnant during the trial will be asked to discontinue with the trial
2. Women at risk of pregnancy (i.e. not on effective contraception – combined oral contraceptive pill, an intrauterine hormonal device or subcutaneous hormonal trial implant)
3. Unable to complete trial documentation, including consent form and symptom diary including those who have difficulty understanding English
4. Already taking Andrographis or other herbal medicine for ARTIs
5. Known immunodeficiency state or undertaking chemotherapy treatment
6. Allergic/hypersensitive to Andrographis or capsule material (cellulose)
7. Already taking medication for ARTIs (paracetamol and ibuprofen will be allowed)
8. Severe hepatic and renal diseases (Chronic Kidney Disease Stage 4, GFR <30), as no adequate data are available on safe use of Andrographis in these conditions
9. Suspected pneumonia (i.e., complicated lower-respiratory-tract infection) on the basis of focal chest signs (focal crepitations, bronchial breathing) and systemic features (high fever, hypoxia, tachypnoea)
10. Serious chronic disorders where antibiotics are needed (e.g. cystic fibrosis, valvular heart disease)
11. Signs of severity which may warrant hospital admission (e.g. SpO2 <91%, systolic BP <90 mmHg, heart rate >130 bpm)
12. Recently/currently involved in a respiratory trial
13. Unable to provide informed consent or complete outcome measures
14. Are already involved in an ongoing trial or have recently been involved in a trial

Date of first enrolment

14/02/2019

Date of final enrolment

06/06/2019

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Aldermoor Health Centre

Aldermoor Close

Southampton

United Kingdom

SO16 5ST

Sponsor information

Organisation

University of Southampton

Sponsor details

Research and Innovation Services

Room 4079

Building 37

Highfield

Southampton

England

United Kingdom

SO17 1BJ

+44 (0)23 8059 5058

rgoinfo@soton.ac.uk

Sponsor type

University/education

ROR

<https://ror.org/01ryk1543>

Funder(s)**Funder type**

Industry

Funder Name

Pukka Herbs (UK)

Results and Publications**Publication and dissemination plan**

The protocol will be available once published. Planned publication of the results in a high-impact peer reviewed journal.

Intention to publish date

31/03/2020

Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date